You Can’t Be Local Everywhere: How the Pursuit of Health Care Sovereignty Is Rewriting Pharma Strategy in APAC

For decades, the pharmaceutical industry operated on a relatively stable premise: innovation was global, manufacturing was concentrated in efficient hubs, and access pathways, while complex, followed broadly predictable rules.

That model is now under strain. Across Asia Pacific (APAC) and beyond, governments are reasserting control over how health care is funded, delivered and supplied, placing greater emphasis on domestic capability, system resilience and locally relevant value. What began as a pandemic-era focus on resilience has evolved into something more structural and strategic.

This shift is increasingly being described as health care sovereignty. It reflects a move by governments to shape not just how medicines are accessed, but how they are produced, evaluated and integrated within national health systems, with greater control over outcomes and dependencies.

This shift is being driven by a convergence of forces. Geopolitical fragmentation is forcing governments to reassess reliance on global supply chains, while post-COVID resilience agendas are prioritising domestic manufacturing and stockpiling. At the same time, fiscal pressure is pushing payers to demand clearer, locally relevant value and advances in artificial intelligence (AI) and real-world data are enabling more nationalised decision-making frameworks.

In Asia Pacific, these dynamics are especially pronounced. India and Indonesia are increasingly embedding localisation into industrial and procurement policy through measures such as Production Linked Incentive schemes and domestic content (TKDN) requirements, while China is reinforcing its domestic ecosystem through mechanisms such as volume-based procurement, alongside broader support for locally developed therapies.

Elsewhere, countries such as Australia, Taiwan and South Korea are increasing expectations around health technology assessment and real-world evidence, with bodies like the Pharmaceutical Benefits Advisory Committee (PBAC) and evolving health technology assessment (HTA) frameworks placing greater emphasis on local data. The direction is clear: health systems are becoming more nationally driven in how they define value, even as the science that underpins them remains global.

The Localisation Paradox

For pharmaceutical companies, this creates a structural tension. Governments increasingly expect a visible, tangible contribution to national systems, whether through local manufacturing, participation in public health priorities, or the generation of locally relevant evidence.

Yet no company can build a deep physical presence in every market. Even the largest multinationals face practical limits, particularly in a region as diverse and fragmented as Southeast Asia. The result is a growing mismatch between expectation and feasibility. Companies are being asked to be local everywhere, without the ability to physically operate everywhere.

From Presence to Participation

This tension is forcing a redefinition of what it means to be “local.” Increasingly, the answer lies not in footprint, but in function, as companies shift from physical presence to embedded value within health systems.

This is most visible in areas such as patient identification and education. Across many APAC markets, underdiagnosis remains high and treatment pathways are becoming more complex, exposing gaps in system capacity. Companies are stepping in not just to support uptake, but to strengthen how care is delivered.

Taken together, this marks a broader shift in how pharma is perceived, from suppliers of medicines to participants in the functioning of health systems.

A More Political Operating Environment

Market access is becoming more political and context-specific, shaped as much by alignment with national priorities as by clinical or economic value. This elevates public affairs and policy engagement to a central role in commercial strategy. Increasingly, it also positions pharmaceutical companies as connective tissue across parts of government that do not always operate in lockstep, helping align health priorities with adjacent agendas such as workforce, productivity and economic development.

At the same time, the diversity of Asia Pacific demands more deliberate choices. Companies must decide where to invest for deep system integration and where to compete with a lighter footprint. In this model, “local” is no longer defined by presence, but by how effectively value is tailored to each market.

What Comes Next

Health care sovereignty is not a temporary phase, nor a purely defensive policy trend. It reflects a deeper reorientation of how governments view health, not just as a social good, but as a pillar of economic security and national resilience.

For pharmaceutical companies, the challenge is no longer simply how to operate across markets, but how to remain relevant within them. Those that succeed will not attempt to replicate a global model everywhere, but will find ways to deliver value that is locally meaningful, even in markets where their physical presence is limited.